

Male Hypogonadism Therapeutic Pipeline Market Review, H2 2016

Male Hypogonadism Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016
/EINPresswire.com/ -- The report
provides comprehensive information
on the therapeutics under
development for Male Hypogonadism,
complete with analysis by stage of
development, drug target, mechanism
of action (MoA), route of
administration (RoA) and molecule
type. The report also covers the
descriptive pharmacological action of



the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619300-male-hypogonadism-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
- The report reviews pipeline therapeutics for Male Hypogonadism by companies and

universities/research institutes based on information derived from company and industryspecific sources

- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects
- The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Male Hypogonadism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Dire

Global Markets Direct Report Coverage 8

Male Hypogonadism Overview 9

Therapeutics Development 10

Pipeline Products for Male Hypogonadism - Overview 10

Pipeline Products for Male Hypogonadism - Comparative Analysis 11

Male Hypogonadism - Therapeutics under Development by Companies 12

Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes 14

Male Hypogonadism - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Male Hypogonadism - Products under Development by Companies 18

Male Hypogonadism - Products under Investigation by Universities/Institutes 20

Male Hypogonadism - Companies Involved in Therapeutics Development 21

Antares Pharma, Inc. 21

Clarus Therapeutics, Inc. 22

Endo Pharmaceuticals Inc. 23

EndoCeutics, Inc. 24

Ferring International Center S.A. 25

Forendo Pharma Limited 26

Lipocine Inc. 27

M et P Pharma AG 28

Merck & Co., Inc. 29

Mereo Biopharma Group Plc 30

Millennium Pharmaceuticals Inc 31

Pantarhei Bioscience BV 32

Repros Therapeutics Inc. 33

Variant Pharmaceuticals, Inc. 34

Male Hypogonadism - Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

BGS-649 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

Access Report @ https://www.wiseguyreports.com/reports/619300-male-hypogonadism-pipeline-review-h2-2016

Get in touch:

LinkedIn: <u>www.linkedin.com/company/4828928</u>
Twitter: <u>https://twitter.com/WiseGuvReports</u>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports

+1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/350390337

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.